Ashish Kamat interviews Shilpa Gupta about the best of ASCO 2024 in advanced bladder cancer. Dr. Gupta discusses three abstracts: the CheckMate-901 trial’s analysis of complete responders to Nivolumab plus gemcitabine-cisplatin in lymph node-only metastatic urothelial cancer; patient-reported outcomes from the EV-302 trial comparing enfortumab vedotin plus pembrolizumab to platinum chemotherapy;…
Efforts are being made to limit nicotine in tobacco products.
The prognosis of acute kidney injury (AKI) in ICU patients might be indicated by levels of a complement factor B fragment.
“We also need to understand and remember that drugs are temporizing measures,” says Wayne Kuang, MD.
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t…
Non-Muscle Invasive Bladder Cancer (2024): Expert Guidance for UrologistsCME Available: auau.auanet.org/node/41961After participating in this CME activity, p…
In this follow-up discussion, Badar Mian and E David Crawford delve deeper into the implications of clinical trials comparing transperineal (TP) and transrectal (TR) prostate…
However, no evidence seen for causal association between alcohol consumption and risk for coronary heart disease, type 2 diabetes
Alicia Morgans interviews Maria De Santis about three studies: the SunRISe-1 trial for non-muscle-invasive bladder cancer, the AMBASSADOR study on adjuvant pembrolizumab for muscle-invasive urothelial…
The detection rate for [99mTc]Tc-HYNIC-iPSMA SPECT imaging was 77.5%.
Men with negative multiparametric magnetic resonance imaging results avoiding biopsy do not have an increased risk for clinically significant prostate cancer.
